Compare IPCA Labs with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs PANACEA BIOTECH - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS PANACEA BIOTECH IPCA LABS/
PANACEA BIOTECH
 
P/E (TTM) x 24.3 17.1 142.1% View Chart
P/BV x 8.7 6.7 130.6% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   PANACEA BIOTECH
EQUITY SHARE DATA
    IPCA LABS
Mar-19
PANACEA BIOTECH
Mar-19
IPCA LABS/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,042354 294.7%   
Low Rs590138 427.0%   
Sales per share (Unadj.) Rs298.674.6 400.5%  
Earnings per share (Unadj.) Rs35.06.7 524.0%  
Cash flow per share (Unadj.) Rs49.415.5 319.0%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs247.157.2 432.0%  
Shares outstanding (eoy) m126.3561.25 206.3%   
Bonus / Rights / Conversions ESOS--  
Price / Sales ratio x2.73.3 82.9%   
Avg P/E ratio x23.336.8 63.3%  
P/CF ratio (eoy) x16.515.9 104.0%  
Price / Book Value ratio x3.34.3 76.8%  
Dividend payout %8.60-   
Avg Mkt Cap Rs m103,10815,061 684.6%   
No. of employees `00013.42.3 580.9%   
Total wages/salary Rs m7,8741,471 535.4%   
Avg. sales/employee Rs Th2,807.01,973.6 142.2%   
Avg. wages/employee Rs Th585.8635.6 92.2%   
Avg. net profit/employee Rs Th329.0176.8 186.1%   
INCOME DATA
Net Sales Rs m37,7324,567 826.2%  
Other income Rs m57745 1,287.5%   
Total revenues Rs m38,3094,612 830.7%   
Gross profit Rs m6,9012,030 340.0%  
Depreciation Rs m1,824540 337.8%   
Interest Rs m1891,048 18.0%   
Profit before tax Rs m5,465486 1,123.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,04277 1,352.0%   
Profit after tax Rs m4,422409 1,081.0%  
Gross profit margin %18.344.4 41.2%  
Effective tax rate %19.115.9 120.3%   
Net profit margin %11.79.0 130.8%  
BALANCE SHEET DATA
Current assets Rs m23,7782,415 984.8%   
Current liabilities Rs m10,9759,077 120.9%   
Net working cap to sales %33.9-145.9 -23.3%  
Current ratio x2.20.3 814.5%  
Inventory Days Days10465 159.4%  
Debtors Days Days6671 93.0%  
Net fixed assets Rs m20,3688,333 244.4%   
Share capital Rs m25361 412.2%   
"Free" reserves Rs m30,9713,443 899.6%   
Net worth Rs m31,2243,504 891.1%   
Long term debt Rs m1,409461 305.4%   
Total assets Rs m45,50713,755 330.8%  
Interest coverage x30.01.5 2,046.7%   
Debt to equity ratio x00.1 34.3%  
Sales to assets ratio x0.80.3 249.7%   
Return on assets %10.110.6 95.6%  
Return on equity %14.211.7 121.3%  
Return on capital %17.338.7 44.8%  
Exports to sales %45.920.9 219.6%   
Imports to sales %16.68.1 203.9%   
Exports (fob) Rs m17,308954 1,814.5%   
Imports (cif) Rs m6,266372 1,684.9%   
Fx inflow Rs m17,3081,203 1,438.7%   
Fx outflow Rs m6,266467 1,342.8%   
Net fx Rs m11,042736 1,499.5%   
CASH FLOW
From Operations Rs m4,9231,049 469.4%  
From Investments Rs m-1,563-54 2,921.7%  
From Financial Activity Rs m-1,832-1,011 181.1%  
Net Cashflow Rs m1,528-20 -7,754.8%  

Share Holding

Indian Promoters % 45.9 74.5 61.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.6 1,900.0%  
FIIs % 25.3 1.3 1,946.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 23.6 73.7%  
Shareholders   36,892 10,259 359.6%  
Pledged promoter(s) holding % 2.1 35.1 6.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PIRAMAL ENTERPRISES  GSK PHARMA  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


May 14, 2021 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS